Abivax (ABVX) Interest Expenses (2024 - 2026)

Abivax's Interest Expenses history runs 3 years deep, the most recent figure standing at -$5.6 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 21.05% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at $128.9 million (up 978.63% YoY), while the FY2025 annual figure was $130.1 million, up 616.4% from the prior year.
• Interest Expenses was -$5.6 million for Q1 2026 at Abivax, down from $249.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $249.4 million in Q4 2025 to a low of -$108.8 million in Q3 2025.
• Historically, Interest Expenses has averaged $15.1 million across 3 years, with a median of -$6.1 million in 2025.
• Biggest YoY gain for Interest Expenses was 594.14% in 2025; the steepest drop was 1068.9% in 2025.
• A 3-year view of Interest Expenses shows it stood at $35.9 million in 2024, then jumped by 594.14% to $249.4 million in 2025, then plunged by 102.24% to -$5.6 million in 2026.
• The last three Interest Expenses figures came in at -$5.6 million (Q1 2026), $249.4 million (Q4 2025), and -$108.8 million (Q3 2025), per Business Quant data.